D&A at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's D&A?
- BioMarin Pharmaceuticals (BMRN) reported D&A of $16.41M in Q1 2026.
- How has BioMarin Pharmaceuticals's D&A changed year-over-year?
- BioMarin Pharmaceuticals's D&A decreased by 25.6% year-over-year, from $22.07M to $16.41M.
- What is the long-term trend for BioMarin Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's D&A has grown at a -7.4% compound annual growth rate (CAGR), from $108.04M to $79.56M.
- What does D&A mean?
- Non-cash expenses related to the wear and tear or expiration of assets.
- How do you interpret D&A?
- High levels relative to revenue may indicate capital-intensive operations or significant past investment in infrastructure.
- How does D&A compare across companies?
- Common in capital-intensive industries; biotech firms with significant manufacturing footprints show higher levels.